Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

Why do some melodies feel instantly right, balanced, memorable and satisfying, even if you have never heard them before? New research from the University of Waterloo suggests that more than creativity ...

One ball on a Plinko board is unpredictable. Drop a thousand and they form a near-perfect bell curve—one of math’s most powerful ideas for 150+ years.

If you're looking for a way to make your next get-together with family and friends more fun, engaging and even educational, ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...

The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid pain medicine Journavx and gene therapy Casgevy. Vertex clocked 11% growth ...

If you're holding shares of Vertex Pharmaceuticals or thinking about adding some to your portfolio, you're not alone in wondering what the right move is. The stock's recent momentum may have caught ...

A 20% drop in Vertex Pharmaceuticals' stock price since I wrote last month was the impetus to make a re-assessment. But the rating has remained unchanged at Hold. This is despite significantly ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...

Vertex Pharmaceuticals (NASDAQ:VRTX) shares fell in premarket trading on Tuesday after the company's VX-993 failed to meet the primary endpoint in the Phase 2 pain study, offsetting a strong quarterly ...